Search

Meet Paul Yoon, Program Coordinator of Spiritual Care at Memorial Sloan Kettering, who immigrated to the US from South Korea, survived cancer, and is navigating his concerns around violence against Asian Americans.

A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.

The combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) has shown improved progression-free survival (PFS) compared with chemotherapy as a first-line treatment for people with a high tumor mutational burden (TMB) in advanced non-small cell lung cancer (NSCLC). Data from the CheckMate -227 trial is being reported by Matthew Hellmann, MD, of Memorial Sloan Kettering Cancer Center, at the AACR Annual Meeting 2018. This research is featured in the meeting’s press program, and findings are being presented in the Clinical Trials Plenary Session, “Immunotherapy Combinations: The New Frontier in Lung Cancer.”

New research funds have been awarded by the RSNA Research & Education Foundation to Robert Young, MD for Using Functional MRI and Diffusion Tensor Imaging of the Language Pathway to Optimize Brain Tumor Resection.

Learn how MSK physician-scientist Christopher Klebanoff is working to bring immunotherapy to more patients, especially those with solid tumors.

Discover the significance of the Josie Robertson Surgery Center’s signature art piece.

Learn how MSK nurse practitioner Mindy Jaffe guides children and young adults with cancer and their families through their reproductive options.

MSK scientists and doctors have the most innovative tools at their disposal to make discoveries and develop better treatments.